Share
   
Title
Code
Session Type
Venue
Date Time
Co-Chairs:
11:00
MOAX0201LB
A randomized controlled trial for the treatment of HIV-associated cryptococcal meningitis in Africa: oral fluconazole plus flucytosine or one week amphotericin-based therapy vs two weeks amphotericin-based therapy. The ACTA Trial
Sile Molloy, United Kingdom
Abstract
Slides
11:15
MOAX0202LB
Dolutegravir / tenofovir / emtricitabine (DTG/TDF/FTC) started in pregnancy is as safe as efavirenz / tenofovir / emtricitabine (EFV/TDF/FTC) in nationwide birth outcomes surveillance in Botswana
Rebecca Zash, United States
Abstract
Slides
11:30
MOAX0203LB
Weekly oral MK-8591 protects male rhesus macaques against repeated low dose intrarectal challenge with SHIVC109P3
Martin Markowitz, United States
Abstract
Slides
11:45
MOAX0204LB
Substantial progress in confronting the HIV epidemic in Swaziland: first evidence of national impact
Rejoice Nkambule, Swaziland
Abstract
Slides
12:00
MOAX0205LB
Safety and efficacy of long-acting CAB and RPV as two drug IM maintenance therapy: LATTE-2 week 96 results
Joseph Eron, United States
Abstract
Slides
12:15
MOAX0206LB
Treatment of chronic hepatitis C genotype 1, 2 and 4 in patients with or without HIV and living in Central or West Africa: the TAC ANRS 12311 trial
Karine Lacombe, France
Abstract
Slides